About NaNose Medical

NaNose Medical develops a breathomics-based platform for early disease detection and staging, initially focusing on lung cancer and liver disease. Their technology uses nanotechnology and AI to analyze volatile biomarkers in breath, creating unique "breath fingerprints" for non-invasive, point-of-care screening. This approach aims to provide a portable, low-cost diagnostic tool for population screening and patient stratification in clinical trials.

```xml <problem> Current diagnostic methods for lung cancer and liver disease often detect the conditions late, reducing treatment effectiveness. Traditional methods can be invasive, costly, and require specialized equipment, limiting accessibility and hindering early intervention. </problem> <solution> NaNose Medical is developing a breathomics platform that uses nanotechnology and artificial intelligence to detect diseases at an early stage through non-invasive breath analysis. The platform analyzes volatile organic compounds (VOCs) in exhaled breath to create unique "breath fingerprints" indicative of specific diseases. This approach offers a portable, user-friendly, and cost-effective solution for early disease screening and patient stratification. The "DiaNose" breath test aims to provide healthcare systems with a tool for earlier identification of liver disease and timely specialist care, while the LUCIA project focuses on improving early detection and management of lung cancer through in-depth risk factor analysis. </solution> <features> - Nanotechnology-based sensors for detecting volatile biomarkers in breath - AI-driven analysis to create disease-specific breath fingerprints - Non-invasive and simple to use, reducing dependency on user skill - Portable handheld device for point-of-care diagnostics - Rapid results for timely intervention - High accuracy in disease detection - Cost-effective solution for mass screening </features> <target_audience> The primary target audience includes healthcare providers, general practitioners, and specialists focused on early disease detection and management of lung cancer and liver disease. </target_audience> ```

What does NaNose Medical do?

How much funding has NaNose Medical raised?

NaNose Medical has raised 642300.

Funding

642300

Employees

8 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

NaNose Medical

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

nanosemed.com 700+

Crunchbase

Funding

Estimated Funding

$500K+

Team (5+)

No team information available.

Company Description

Problem

Current diagnostic methods for lung cancer and liver disease often detect the conditions late, reducing treatment effectiveness. Traditional methods can be invasive, costly, and require specialized equipment, limiting accessibility and hindering early intervention.

Solution

NaNose Medical is developing a breathomics platform that uses nanotechnology and artificial intelligence to detect diseases at an early stage through non-invasive breath analysis. The platform analyzes volatile organic compounds (VOCs) in exhaled breath to create unique "breath fingerprints" indicative of specific diseases. This approach offers a portable, user-friendly, and cost-effective solution for early disease screening and patient stratification. The "DiaNose" breath test aims to provide healthcare systems with a tool for earlier identification of liver disease and timely specialist care, while the LUCIA project focuses on improving early detection and management of lung cancer through in-depth risk factor analysis.

Features

Nanotechnology-based sensors for detecting volatile biomarkers in breath

AI-driven analysis to create disease-specific breath fingerprints

Non-invasive and simple to use, reducing dependency on user skill

Portable handheld device for point-of-care diagnostics

Rapid results for timely intervention

High accuracy in disease detection

Cost-effective solution for mass screening

Target Audience

The primary target audience includes healthcare providers, general practitioners, and specialists focused on early disease detection and management of lung cancer and liver disease.